BiotechTube
DotLab

DotLab

New York, United States· Est.
dotlab.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $25.5M

Overview

DotLab is a private, US-based diagnostics company founded in 2015 to tackle the chronic under-diagnosis of endometriosis. Its core innovation is the DotEndo test, a first-of-its-kind blood test that analyzes microRNA signatures to identify active disease, potentially reducing the decade-long diagnostic delay. The company is currently in the commercial rollout phase, making the test available to select providers while continuing to validate it through clinical studies like the EMPOWER trial.

Women's HealthEndometriosis

Technology Platform

Proprietary blood test analyzing a panel of six microRNA biomarkers to identify active endometriosis, using biostatistical algorithms for a binary result.

Funding History

4
Total raised:$25.5M
Series A$10M
Series A$10M
Seed$3M
Seed$2.5M

Opportunities

The primary opportunity is addressing the vast, underserved market of endometriosis diagnosis, potentially reducing the 10-year diagnostic delay for millions of women globally.
Success could establish a platform for expanding into other under-diagnosed women's health conditions.

Risk Factors

Key risks include the need for robust validation from the ongoing EMPOWER study, challenges in changing clinical practice and securing insurance reimbursement, and potential future competition from other non-invasive diagnostic approaches.

Competitive Landscape

DotEndo appears to be a first-mover as a commercially available blood test for endometriosis. Competition includes other research-stage non-invasive diagnostics (e.g., other miRNA, proteomic tests) and the entrenched standard of laparoscopic surgery. The landscape is nascent but likely to become more competitive.

More companies in Diagnostics & Precision Medicine →More companies in United States →